Command Palette

Search for a command to run...

BROOKS
126.01(+0.96%)
1W: -7.03%

Brooks Laboratories Peer Comparison

Snapshot Summary

Brooks Laboratories Ltd. is underperforming its peers in terms of profitability and valuation metrics, primarily due to negative earnings and high PE ratio. However, it shows impressive revenue growth, suggesting potential for recovery. In contrast, companies like Cipla Ltd. and Dr. Reddy's Laboratories Ltd. are strong performers with solid profitability and reasonable valuation, making them attractive for investors.

  • Brooks Laboratories shows high revenue growth (25.76% YoY), but has negative EPS and ROE.
  • Cipla Ltd. and Dr. Reddy's Laboratories Ltd. lead in profitability with strong EPS and ROE.
  • Divi's Laboratories is the most overvalued based on PE ratio (73.20) despite decent margins.
  • Sun Pharmaceutical and Mankind Pharma show good growth and reasonable valuations.
  • Cipla Ltd.: Strong profitability metrics with a low PE ratio, making it attractive for investors.
  • Dr. Reddy's Laboratories Ltd.: Excellent ROE and strong growth in EPS, indicating solid financial health.
  • Mankind Pharma Ltd.: High revenue growth and strong margins, suggesting effective operational management.
Stocks
CMP
Market Cap
P/E
ROCE (%)
Debt/Equity
BROOKS₹138.90₹409.16Cr134.02-24.92%0.08
SUNPHARMA₹1,563.35₹3,75,099.26Cr87.5917.60%0.04
DIVISLAB₹6,091.05₹1,61,698.50Cr73.2016.46%-
CIPLA₹1,587.60₹1,28,217.27Cr23.7322.77%0.01
TORNTPHARM₹3,581.55₹1,21,215.77Cr61.5324.28%0.57
DRREDDY₹1,280.30₹1,06,835.27Cr15.5026.86%0.07
MANKIND₹2,518.95₹1,03,926.59Cr55.1828.38%0.02

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.